Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Switching to A1811 vs. Continuation of the Original Neoadjuvant Regimen After THP Induction in HER2-Positive Breast Cancer

NCT07844291 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07844291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07844291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Switching to A1811 vs. Continuation of the Original Neoadjuvant Regimen After THP Induction in HER2-Positive Breast Cancer
Lead sponsor
Peking University People's Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
December 31, 2031
Enrollment
432 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer (early breast cancer)